🔴 ACADIA Pharmaceuticals is trading 4.12% down today despite biotech gains

ACADIA Pharmaceuticals is trading 4.12% down at $29.31 despite biotechnology’s 2.06% advance and broadly flat major indexes.

• No new company-specific negative catalyst has been identified for August 26, 2026.
• The European Commission approved DAYBU on August 24; H.C. Wainwright reiterated a Buy rating and $37 price target on August 25.
• The move points to an unexplained company-level pullback rather than sector-wide weakness.